COVID-19 vaccine eligibility

Vaccines are safe and effective and help protect you and those around you from serious COVID-19 illness. In Ontario, you are considered up to date with your COVID-19 vaccines when you have completed your primary series and have received a COVID-19 vaccine within the last 6 months. The time between when you receive your doses is dependent on the vaccine you receive, your age, your health status, and if you recently had a COVID-19 infection.

Read on to determine if you are up to date with your COVID-19 vaccines.

Stay up to date

Get vaccinated against COVID-19. It is highly recommended you receive all COVID-19 vaccines, including recommended booster dose(s) to stay up to date and to build long-term protection against COVID-19.

Staying up to date is made easy with the Ministry of Health’s eligibility table (pg 5 and 6).

Table 1: COVID-19 vaccine eligibility

AgeRecommended IntervalsAMinimum IntervalsA
6 months to 4 years Primary Series

Monovalent Pfizer-BioNTech (3 mcg)

• Second dose, 56 days after first dose
• Third dose, 56 days after second dose

Monovalent Moderna (25 mcg)

• Second dose, 56 days after first dose

Booster Doses – not eligible

Primary Series

Monovalent Pfizer-BioNTech (3 mcg)

• Second dose, 21 days after first dose
• Third dose, 56 days after second dose

Monovalent Moderna (25 mcg)

• Second dose, 28 days after first dose

Booster Doses – not eligible
Immunocompromised individuals 6 months to 4 years Primary Series

Monovalent Pfizer-BioNTech Comirnaty (3 mcg)

• Second dose, 56 days after first dose
• Third dose, 56 days after second dose
- Fourth dose, 56 days after third dose

Monovalent Moderna Spikevax (25 mcg)

• Second dose, 56 days after first dose
• Third dose, 56 days after second dose

Booster Doses – not eligible
Primary Series

Monovalent Pfizer-BioNTech Comirnaty (3 mcg)

• Second dose, 21 days after first dose
• Third dose, 56 days after second dose
- Fourth dose, 56 days after third dose
Monovalent Moderna Spikevax (25 mcg)

• Second dose, 28 days after first dose
• Third dose, 28 days after second dose

Booster Doses – not eligible
5 years and older Primary Series

• Second dose, 56 days after first dose

Booster Doses*

• 6 months (168 days) after last dose
Primary Series

• Second dose, 28 days after first dose

Booster Doses*

• 3 months (84 days) after last dose
Immunocompromised individuals 5 years and older Primary Series

• Second dose, 56 days after first dose
• Third dose, 56 days after second dose

Booster Doses*

• 6 months (168 days) after last dose
Primary Series

• Second dose, 28 days after first dose
• Third dose, 28 days after second dose

Booster Doses*

• 3 months (84 days) after last dose

A Evidence shows that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness.

* Please note that individuals who become infected with COVID-19 will be recommended to make modifications to the intervals above. Please read the Vaccination after COVID-19 infection section below for more information.

* Please note that individuals who are a member of a specified high-risk group will be recommended to make modifications to the booster dose intervals above. Please read the booster dose section below for more information.

COVID-19 Vaccine Product Preferences

The National Advisory Committee on Immunization (NACI) preferentially recommends receipt of monovalent mRNA COVID-19 vaccines to complete a primary series for all individuals 6 months and older, without contraindications to the vaccine.

Table 2: mRNA COVID-19 Vaccine Product Preferences for Primary Series

AgeProduct Preference (mcg/mL)
6 months to 4 yearsNo preference between monovalent Pfizer-BioNTech Comirnaty (3mcg / 0.2mL) or monovalent Moderna Spikevax (25mcg / 0.25mL) for healthy children.
For those that are immunocompromised, monovalent Moderna Spikevax (25mcg / 0.25mL) is the preferred product.*
5 to 11 yearsFor healthy children, the preferential recommendation is to be immunized with monovalent Pfizer BioNTech Comirnaty (10mcg / 0.2mL).
For immunocompromised children and for those between the ages of 5 years to 11 years, the preferential recommendation is to be immunized with monovalent Pfizer BioNTech Comirnaty (10mcg / 0.2mL), however children between 6 and 11 years of age may receive monovalent Moderna (50mcg / 0.25mL) based on clinical discretion.
12 to 29 yearsFor healthy individuals, the preferential recommendation is to be immunized with monovalent Pfizer BioNTech Comirnaty (30mcg / 0.3mL) but may receive monovalent Moderna Spikevax (100mcg / 0.5mL) based on clinical discretion.
30 years and olderNo preference between monovalent Pfizer BioNTech Comirnaty (30mcg / 0.3mL) or monovalent Moderna Spikevax (100mcg / 0.5mL)

*The preferential recommendation for monovalent Moderna (25mcg) is due to feasibility of series completion rather than any safety signals observed. A 4-dose primary series may have feasibility challenges including the need to schedule 4 separate appointments and space appointments appropriately relative to other childhood vaccination appointments.

Table 3: mRNA COVID-19 Vaccine Product Preferences for Booster Doses

The Ontario Ministry of Health recommends individuals receive an mRNA booster dose due to the strong protection offered and well established safety and effectiveness data.

AgeProduct Preference (mcg/mL)
6 months to 4 yearsNot applicable as these children are not eligible to receive a booster dose.
5 to 11 yearsMonovalent Pfizer BioNTech Comirnaty (10mcg / 0.2mL) is the only product authorized for this age group.
12 to 17 yearsBivalent Pfizer-BioNTech Comirnaty (30mcg / 0.3mL) is the only authorized bivalent product for this age group.
Bivalent Moderna Spikevax (50 mcg / 0.5mL) may be administered to those that are immunocompromised as an off-label vaccine and with informed consent.
18 years and olderNo preference between bivalent Pfizer BioNTech Comirnaty (30 mcg / 0.3mL) or bivalent Moderna Spikevax (100 mcg / 0.5 mL).

Expand All

Close All


This item was last modified on November 22, 2022